Patients taking weekly injectable efalizumab for psoriasis have an increased risk of serious and life-threatening infections, according to the US Food and Drug Administration (FDA). The agency announced in October that a boxed warning is being added to the product's label.
The FDA has received reports of patients treated with this drug developing bacterial sepsis, viral meningitis, invasive fungal disease, progressive multifocal leukoencephalopathy, and other opportunistic infections. Some patients were hospitalized and some died.
Kuehn BM. Psoriasis Drug Warning. JAMA. 2008;300(20):2359. doi:10.1001/jama.2008.645
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: